A recommended approach to evaluate cardiovascular risk and to prevent cardiovascular diseases and type 2 diabetes mellitus in women with polycystic ovary syndrome;Doporučený postup k posouzení kardiovaskulá rního rizika a prevenci kardiovaskulárních onemocnění a diabetes mellitus 2. typu u žen se syndromem polycystických ovarií

Vnitrni Lekarstvi

Volumn 58, Issue 1, 2012, Pages 56-57

  Vrbíkova, Jana ^a   Fanta, M ^b   Pelikanova T ^c   Skrha J ^d   Marek, J ^d  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cardiovascular risk factors; Ischaemic heart disease risk factors; Polycystic ovary syndrome; Prevention of diabetes mellitus

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FEMALE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PRIMARY PREVENTION; SCREENING;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME; RISK ASSESSMENT;

EID: 84857020741     PISSN: 0042773X     EISSN: 18017592     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Wild RA, Carmina E, Diamanti-Kandarakis E et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95: 2038-2049.
2. Moran LJ, Misso ML, Wild RA et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347-363.
3. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111: 607-613. (Pubitemid 34088070)
4. Mosca L Guidelines for prevention of cardiovascular disease in women: a summary of recommendations. Prev Cardiol 2007; 10 (Suppl 4): 19-25.
5. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rationale approach. In: Dunaif A, GivensJR, Haseltine FP et al (eds). Polycystic ovary syndrome. Boston, USA: Blackwell Scientific 1992: 377-384.
6. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
7. Azziz R, Carmina E, Dewailly D et al. Androgen Excess Society. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245. (Pubitemid 44833391)
8. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181-197.
9. Widimstý jr. J, Cífková R, Špinar J et al. Ceskou Spolecnost Pro Hypertenzi. Recommended diagnostic and therapeutic approach in arterial hypertension - 2007 version. Recommendations of the Czech Hypertension Society. Vnitř Lék 2008; 54: 101-118.